Soft Tissue Infections Clinical Trials

A listing of Soft Tissue Infections medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Arizona

UPDATED

Phoenix Arizona 85008

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Tucson Arizona 24857

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

California

UPDATED

Loma Linda California 92354

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Los Angeles California 90033

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Los Angeles California 90502

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Los Angeles California 90033

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Orange California 92868

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

View More ▼

UPDATED

Sacramento California 95817

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

San Diego California 92123

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

UPDATED

San Diego California 92103

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Colorado

UPDATED

Denver Colorado 80045

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Denver Colorado 80204

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Connecticut

UPDATED

New Haven Connecticut 06520

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

District of Columbia

UPDATED

Washington District of Columbia 20010

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Florida

UPDATED

Gainesville Florida 32610

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Miami Florida 33136

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Georgia

UPDATED

Augusta Georgia 30909

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Iowa

UPDATED

Iowa City Iowa 52242

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Kentucky

University of Kentucky Chandler Medical Center
Lexington Kentucky 40536

Research Study for Patients with Radiation Necrosis

View More ▼

UPDATED

Lexington Kentucky 40536

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Louisiana

UPDATED

Baton Rouge Louisiana 70808

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

New Orleans Louisiana 70112

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Maine

UPDATED

Portland Maine 04102

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Maryland

UPDATED

Baltimore Maryland 21201

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Massachusetts

UPDATED

Boston Massachusetts 02115

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Boston Massachusetts 02114

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Michigan

UPDATED

Ann Arbor Michigan 48109

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Detroit Michigan 48202

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Detroit Michigan 48235

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Detroit Michigan 48201

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Royal Oak Michigan 48073

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

Minnesota

UPDATED

Minneapolis Minnesota 55455

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

St. Paul Minnesota 55101

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Missouri

UPDATED

Columbia Missouri 65211

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Kansas City Missouri 64108

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

New Jersey

UPDATED

Camden New Jersey 08103

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

New Mexico

UPDATED

Albuquerque New Mexico 87106

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

New York

View More ▼

UPDATED

Bronx New York 10461

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Bronx New York 10467

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Buffalo New York 14215

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Staten Island New York 10305

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

North Carolina

UPDATED

Charlotte North Carolina 28208

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Greenville North Carolina 27834

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

Ohio

UPDATED

Cincinnati Ohio 45219

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Cleveland Ohio 44109

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Columbus Ohio 43210

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Dayton Ohio 45409

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene

UPDATED

Toledo Ohio 43606

A clinical trial to evaluate treatments using Tedizolid Phophate 200 mg, IV to oral for 6 days and Antibiotic comparator for patients with Skin Diseases, Infectious or Skin Diseases, Bacterial Skin Diseases (cSSTI)

View More ▼

UPDATED

Youngstown Ohio 44501

Patients are needed to participate in a clinical research study of AB103 0.5 mg/kg and NaCl 0.9% to evaluate Necrotizing Soft Tissue Infections, Necrotizing Fasciitis or Fournier's Gangrene